On May 29, 2018 BerGenBio ASA (OSE: BGBIO) reported it will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib (Press release, BerGenBio, MAY 29, 2018, View Source [SID1234527034]). The data will be presented at the Annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting and at a reception hosted by BerGenBio (details below).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call details:
The call will be hosted by BerGenBio senior management and take place on:
Monday, 4 June 2018 at 8:30 AM CEST.
To take part, please dial in 5-10 minutes prior to the scheduled start using below phone number and confirmation code 1068189:

Norway +47 2100 2608
United Kingdom +44 (0)330 336 9106
United States +1 323-794-2594

A slide deck presentation to accompany the call will be made available at www.bergenbio.com in the Investors / Presentations section from 8:00 AM CEST on 4 June 2018.

Presentations to be made during the annual ASCO (Free ASCO Whitepaper) meeting:
Saturday 2 June, 6:00 – 8:00 PM CDT, Chicago School of the Art Institute, Chicago, IL
BerGenBio private reception

New interim Phase II clinical trial data with bemcentinib and selected pre-clinical data to be discussed by BerGenBio principal investigators and invited key opinion leaders
For further details and to receive an invitation, please click here
Monday 4 June, 8:00 AM – 11:30 AM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBC008 – Poster Board: #292, Abstract 3078
Interim clinical data from clinical trial ref. BGBC003 – Poster Board: #80, Abstract 7020
To be discussed at the Poster Discussion Session. 11:30 AM – 12:45 PM
Biomarker study – Poster Board: #385, Abstract 2559
Monday 4 June, 1:15 PM – 4:45 PM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBIL006 – Poster Board: #375, Abstract 9548
The posters presented at ASCO (Free ASCO Whitepaper) will be made available www.bergenbio.com in the Investors / Presentations section at the time of presentation.